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Abstract
Background: IL28B polymorphisms are predictors of therapy response in
hepatitis C virus (HCV) patients. We do not know whether they are markers
of treatment response in admixed populations or not. Aims: To determine
whether IL28B polymorphisms are predictors of therapy response in patients
with HCV from an admixed population and are influenced by genetic ances-
try. Methods: rs12979860 and rs8099917 were genotyped in 222 HCV
patients treated with pegylated interferon and ribavirin. Ancestry was deter-
mined using genetic markers. Results: IL28B rs12979860 C/C was associated
with sustained virological response (SVR), whereas C/T and T/T were associ-
ated with failure to therapy (P = 1.12 9 105). IL28B rs8099917 T/T was
associated with SVR, and G/G and G/T were associated with nonresponse/
relapse (NR/R) (P = 8.00 9 103). Among HCV genotype 1 patients with
C/C genotype, genomic ancestry did not interfere with therapy response.
Among patients with rs12979860 T/T genotype, African genetic contribution
was greater in the NR/R group (P = 1.51 9 103), whereas Amerindian
and European genetic ancestry contribution were higher in the SVR
group (P = 3.77 9 103 and P = 2.16 9 102 respectively). Among HCV
type 1 patients with rs8099917 T/T, African genetic contribution was signifi-
cantly greater in the NR/R group (P = 5.0 9 103); Amerindian and Euro-
pean ancestry genetic contribution were greater in the SVR group.
Conclusion: IL28B rs12979860 and rs8099917 polymorphisms were predictors
of therapy response in HCV genotypes 1, 2 and 3 subjects from an admixed
population. Genomic ancestry did not interfere with response to therapy in
patients with rs12979860 C/C, whereas it interfered in patients with C/T and
T/T genotypes. Among HCV genotype 1 rs8099917 T/T patients, genomic
ancestry interfered with response to therapy.
Infection by hepatitis C virus (HCV) is a worldwide
endemic disease, an important aetiology of cirrhosis and
hepatocellular carcinoma, and is the leading cause of
liver transplantation in adults (1, 2). Treatment with
pegylated interferon alpha associated with ribavirin for
48 weeks is recommended for patients infected with
HCV genotype 1 with a sustained virological response
(SVR) rate of approximately 50%, whereas subjects
infected with HCV genotypes 2 or 3 may be treated for
24 weeks, and the SVR rate may be as high as 80%
(3–5). Host characteristics such as advanced liver fibro-
sis, male gender, insulin resistance, absence of adherence
to therapy, co-infection with hepatitis B or HIV, liver
iron overload, are associated with lower SVR rates (6).
In addition, several studies have shown that ancestry
influences antiviral therapy response, and African
descendants have lower SVR rates compared with whites
(7, 8). Of note, known factors like therapy adherence,
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HCV genotype, kind of pegylated interferon or social
status cannot explain these differences (9). Variations in
genetic and immunological background possibly explain
these differences and they can be useful as therapy
response markers.
Several genome-wide association studies (GWAS)
have observed that numerous single nucleotides poly-
morphisms (SNP) affect interferon drug response and
also the spontaneous viral clearance to HCV. Recently,
the IL28B gene polymorphisms have been reported as
the strongest predictor of HCV therapy response, early
viral kinetics and spontaneous viral clearance, and they
might explain part of the association among therapy
response and the host ethnicity (10–16). IL28B contrib-
utes to viral resistance and is known to be unregulated
by interferon and by RNA virus infection. In addition,
polymorphisms in MxA, osteopontin and KIR receptor
genes have been reported to be associated with inter-
feron response (17–19).
The rs12979860 IL28B variant was strongly associated
with SVR in HCV genotype 1 infected North Americans.
In patients of European ancestry, the C/C genotype was
associated with a two-fold greater rate of SVR than the
T/T genotype, three-fold in the African American and
two-fold in Hispanic population groups, and when C/C
genotype was compared with other host variables as
baseline viral load, liver fibrosis and ethnicity, the IL28B
polymorphism was strongly and independently associ-
ated with therapy response (10). The C allele is more
frequently found in European ancestry people, and then
it was hypothesized that part of the differences in SVR
rates could be accounted for by the difference in fre-
quency of the C allele between African Americans and
individuals of European ancestry. Studies have showed
that African American patients with the C/C genotype
had a significantly higher rate of SVR than European
Americans who were non-C/C (10). Data showed that
genotype 1 chronic hepatitis C (CHC) in Asian subjects
is associated with higher rates of virological response
compared with that in Caucasians and frequency of
IL28B alleles, and genotypes may explain this differences
(20). Other IL28B polymorphisms (rs12980275 and
rs8099917) have been studied and the non-favourable
alleles were strongly associated with virological non-
response to HCV therapy in Japanese population (OR
20.3 and OR 30.0 respectively) (11). Allele G from
IL28B at rs8099917 is more frequent in Asiatic popula-
tion, and probably this is the reason that the predictive
value of these polymorphisms in the Japanese study
appears to be stronger than those observed in the studies
of African and European Americans.
In HCV genotype 2 or 3 infected patients, the role of
IL28B gene polymorphisms is uncertain, especially if we
consider their different variants. A multicentre trial that
characterized IL28B at rs1297960 in 268 Caucasian con-
cluded that IL28B polymorphism was associated with
SVR in patients who did not achieve a rapid virological
response (RVR) (21).
Of note, the frequency of IL28B alleles in admixed
populations from different geographical regions is not
known. There is no data showing that IL28B polymor-
phisms can be applied as a predictor of HCV antiviral
therapy response in populations highly admixed from
Europeans, Africans and Amerindians.
In this study, two IL28B SNPs were analysed with
regard to therapy response and ancestry in a diverse
sample stratified in two groups: HCV genotype 1 and
HCV genotypes 2 plus 3. The IL28B variant, rs12979860
(T > C), is upstream of the IL28B gene. Another vari-
ant, rs8099917 (T > G), is located in 80-kilobase region,
encoding three cytokines (IL-28B, IL-28A and IL-29).
The aim of this study was to analyse association between
IL28B SNPs and HCV therapy response in an admixed
population.
Materials and methods
Study design and patients
This is a case–control concurrent study. Between January
2010 and March 2011, 283 adult patients chronically
infected with HCV genotypes 1, 2 and 3 from the out-
patient clinic, who had been treated with a combination of
pegylated interferon alpha-2a or alpha-2b and ribavirin,
were consecutively screened. Among them, 222 were
enrolled in the protocol, and 61 were not included because
of ongoing antiviral therapy, co-infection with HIV/HBV
or incomplete data. This study was approved by the insti-
tution’s ethics committee, and all patients provided writ-
ten informed consent. All procedures were conducted in
accordance with provisions of the Declaration of Helsinki.
Inclusion criteria
Patients with CHC with viral genotype 1, 2 or 3; older
than 18 years who were treated with combination anti-
viral therapy with pegylated interferon alpha 2a or 2b
plus ribavirin.
Exclusion criteria
Hepatitis B or HIV co-infection; alcohol intake  40 g
ethanol/day or other concomitant chronic liver diseases.
Hepatitis C virus genotype was determined using
the Inno-LiPA HCV assay (Innogenetics, Zwijnaarde,
Belgium) and the chronic infection was defined by
detectable HCV RNA for at least 6 months (using the
COBAS® AMPLICOR HCV Test, v2.0, Roche Molecular
Systems, Pleasanton, CA, USA). SVR was defined as
undetectable HCV RNA in serum 24 weeks after discon-
tinuation of therapy. Patients infected with HCV geno-
types 2 or 3 were treated for 24 weeks and patients with
HCV genotype 1 received 48 weeks of treatment. Non-
response to therapy was defined as HCV viral load
decline less than 2 logs at week 12 during therapy or
detectable serum HCV RNA at any other time during
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therapy up to 48 weeks. Relapse was defined as unde-
tectable HCV RNA in serum at the end of therapy fol-
lowed by detectable HCV RNA after discontinuation of
therapy. For analysis, we separated patients into two
groups: SVR (including individuals who achieved SVR)
and non-response/relapse (NR/R) (with individuals
who were non-responder or relapse to therapy). Liver
biopsies were reviewed only by one pathologist using
the Metavir scoring system and variables considered for
analysis were: mild and moderate (F0–F2) and severe
(F3–F4) liver fibrosis (22). Other data were obtained
from patient’s interview and charge review.
DNA extraction
Samples of peripheral blood from each subject were col-
lected in 0.5 M EDTA tubes, and genomic DNA was
extracted from mononuclear cells using the PureLink
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
IL28B genotyping
The rs12979860 and rs8099917 were genotyped using
the ABI TaqMan SNP genotyping assays (Applied Bio-
systems, Foster City, CA, USA) and predesigned com-
mercial genotyping assays (ABI assay C_11710096_10).
The PCR reactions were performed in 96-well micro-
plates with ABI 7300 Real-Time PCR (Applied Bio-
systems). Allele discrimination was achieved by
fluorescence detection using SDS software version 1.3.1
(Applied Biosystems).
Ancestry analysis
Ancestry informative markers
Genetic ancestry was determined by analysing seven
ancestry informative markers (AIMs), and the allele*1
was defined as the presence of insertion or the lack of
restriction enzyme site (23). The AIMs used were
selected based on previous studies that analysed a panel
of 48 ancestry markers in different populations (23, 24).
We chose seven AIMs with the largest ethnic-geographi-
cal differential frequencies (higher than 48%). The Alu
insertion and indel polymorphisms were detected using
conventional PCR, and SNPs were detected using Real-
Time PCR (TaqMan™ System by Applied Biosystems).
The AIMs analysed were: African ancestry, AT3-I/D
(76bp indel, locus 1q25.1, rs3138521) and LPL [T > C
(SNP), locus 8p21.3, rs285](25); European ancestry,
Sb19.3 (Alu insertion, locus 19p12, rs3138524), APO (Alu
insertion, locus 11q23.3, rs3138522) and FY-Null [A > G
(SNP), locus 1q23.2, rs2814778]; and Amerindian ances-
try markers, PV92 (Alu insertion, locus 16q23.3,
rs3138523), CKMM [C > T (SNP), locus 19q13.32,
rs4884] (24, 25). In analysis, the allele*1 frequency in
each genetic ancestry marker studied was considered.
Ancestral population
A total of 482 participants comprising the ancestral pop-
ulations were used as reference groups in the genetic
ancestry analysis. The African ancestral population con-
sisted of 134 Nigerians; the European ancestral popula-
tion consisted of 23 Germans and 83 Spanish; the
Amerindian ancestral population consisted of 242
Native Americans. These samples were kindly provided
by Mark Shriver, MD, PHD. All ancestry markers analy-
sed in this study population were also tested in the
ancestral population.
Morphological phenotypic ancestry
Two trained researchers performed the morphological
phenotypic classification of ancestry using the Krieger’s
and Parra’s criteria (26, 27). These criteria evaluate skin
colour (white, brown or black), nose shape (prominent
or upturned tip, depressed tip or flat), lip thickness
(thin, medium or thick) and hair texture (straight, wavy
or curly hair). People were classified according to their
phenotypic characteristics as white, mulatto (a person
who has both black and white phenotypic ancestry) or
black. If a person had a combination of white skin col-
our, upturned nose tip, fine lips and straight hair, they
were classified phenotypically as white; if they had black
skin colour, flat nose, thick lips and curly hair, they were
classified as black. If they had intermediate or mixed
characteristics, they were classified as mulatto. An atlas
of the human race was used to define and classify partic-
ipants’ nose and lip shapes (28).
Self-reported ancestry (self-classification of race/colour)
Patients defined themselves as white, mulatto, black or
other (Amerindian or Asian) according to race/colour
classification from Brazilian Institute of Geography and
Statistics (IBGE) (29).
The patients were divided into two groups based on
their phenotypic and self-reported ancestries: whites
and African descendants (composed of mulattos and
blacks).
Statistical analyses
The sample size was estimated to obtain a statistical
power of 80% to detect an association between IL28B
and response to antiviral therapy (SVR and NR/R).
Two-sided tests were utilized with an alpha value of 0.05
and a confidence interval of 95%. To describe the study
sample, we used proportions for categorical variables, as
well as median, mean and standard deviation for contin-
uous variables. Proportions were compared using the
Chi-square test and Fisher’s exact test. Continuous
variables were compared using Student’s t-test for para-
metric variables and the Mann–Whitney test, when
the distributions were not parametric. As a result of a
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concern that there was collinearity between IL28B vari-
ants and also among genetic ancestries, they were analy-
sed separately. The R PROJECTS software version 2.11.1 for
Windows (31 May 2010, Statistics Department of the
University of Auckland, Auckland, New Zealand, http://
www.r-project) was used to analyse these data. Allele
frequencies and analysis of differentiation between
groups were performed using the GENEPOP online version
4.0.10 (Laboratiore de Genetique et Environment,
Montpellier, France) (30). Estimation of ancestral con-
tribution was calculated using the ADMIX95 software
(Departamento de Genética de la Facultad de Medicina,
Universidad de la Repu´blica, Montevideo, Uruguay,
www.genetica.fmed.edu.uy) (31) and the estimation of
ancestry contribution of each individual was calculated
using the STRUCTURE software version 2.2 (Department of
Human Genetics, University of Chicago, Chicago, IL,
USA) (32).
Results
The sample comprised 222 subjects; 88 (39.6%) had
achieved SVR, 106 (47.7%) were non-responders and 28
(12.7%) were relapsers to antiviral therapy. A total of
139 patients (62.6%) were males and 83 (37.4%) were
females; 102 (53.7%) patients had Metavir score F3/F4.
There were 166 (74.7%) subjects infected by HCV geno-
type 1, and among them, 60 (36.1%) were sustained
virological responders; 56 (25.3%) were infected by
HCV genotypes 2 or 3 and 28 of them (50%) had
achieved SVR.
Factors associated with therapy failure at baseline
included severe liver fibrosis (OR 2.19, P = 1.10 9
102), HCV genotype 1 (OR 1.77, P = 4.50 9 102)
and HCV viral load (P = 4.47 9 102). There were no
significant associations between therapy response and
gender, age or aminotransferase levels (Table 1).
Our study population was admixed and tri-hybrid,
with the genetic contribution of European (0.333),
Amerindian (0.217) and especially African genetic con-
tribution (0.450). The AIMs – APO, PV92 and LPL were
in Hardy–Weinberg equilibrium (P = 0.06, 0.18 and
0.59 respectively). Frequencies of AIMs in the ancestral
populations and from our population with CHC are
described in Table 2. African genetic ancestry contribu-
tion was associated to therapy failure (P = 1.89 9 103)
and Amerindian genetic ancestry contribution was asso-
ciated to SVR (P = 5.86 9 106) (Table 1). When the
same analysis was performed in the subgroup of HCV
genotype 1 infected patients, the results were similar
Table 1. Baseline characteristics of patients with chronic hepatitis C according to antiviral therapy response
SVR, n = 88 (39.6%) NR/R, n = 134 (60.4%) P OR CI 95%
Age, y 52 (46.3; 56.8) 52.5 (47; 59.8) 0.25
Gender, n (%)
Male 60 (43.2) 79 (56.8) 0.20 1.49 0.85–2.63
Female 28 (33.7) 55 (66.3)
Ancestry classification
Genetic ancestry contribution (mean)
European 0.336 0.329 0.45
Amerindian 0.324 0.287 5.86 9 106
African 0.335 0.374 1.89 9 103
Self-reported ancestry, n (%)
Whites 32 (47.8) 35 (52.2) 0.14 1.57 0.88–2.80
African-descendans 56 (36.8) 96 (63.2)
Missing 0 03
Phenotypic ancestry, n (%)
Whites 41 (45.6) 49 (54.4) 0.21 1.46 0.84–2.53
African-descendans 47 (36.4) 82 (63.6)
Missing 0 03
HCV genotype n (%)
1 60 (36.1) 106 (63.9) 4.50 9 102 1.77 0.96–3.26
2/3 28 (50.0) 28 (50.0)
Liver fibrosis (Metavir) n (%)
F0–F2 42 (47.7) 46 (52.3) 1.10 9 102 2.19 1.21–3.98
F3–F4 30 (29.4) 72 (70.6)
Missing 16 16
HCV RNA viral load (IU/L)(Log10) 5.58 (5.1; 5.9) 5.93 (5.6; 6.1) 4.47 9 10
2
ALT (IU/L)* 97 (64; 148) 97 (61; 139.3) 1.00
AST (IU/L)* 69 (53; 89) 76.5 (50.8; 100.3) 0.89
Age, AST, ALT, HCV viral load were showed as median (p25; p75).
*Alanine aminotransferasis (ALT) and aspartato aminotransferasis (AST) normal values were 40 UI/L.
CI 95%, confidence interval 95%; NR/R, non-response or relapse; P, P-value; OR, odds ratio; SVR, sustained virological response.
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and the NR/R group had a higher contribution of Afri-
can genetic ancestry than the SVR group (0.381 vs
0.334, respectively, P = 2.0 9 103), whereas in the
SVR group, there was a predominance of Amerindian
ancestry compared with the NR/R group (0.281 vs
0.323, P = 1.64 9 105). There was no difference
between the amount of European contribution (0.323 in
NR/R and 0.335 in SVR group, P = 0.23). Among the
HCV genotype 2/3 subgroup of patients, we did not
observe differences in the genetic ancestry contribution
among NR/R and SVR groups: Amerindian contribu-
tion was 0.325 in the NR/R group and 0.351 in the SVR
group, P = 0.23; European, 0.331 in the NR/R and
0.302 in the SVR group, P = 0.15; African 0.342 and
0.357 in the NR/R and SVR groups respectively;
P = 0.59. There was no significant association between
therapy response and self-reported and phenotypic
ancestries (Table 1).
IL28B
The IL28B rs12979860 was analysed in 221 subjects, and
rs8099917 was analysed in 222 subjects. Both IL28B
SNPs were in Hardy–Weinberg equilibrium (rs8099917,
P = 1.00; rs12979860, P = 0.38), but analysis of linkage
disequilibrium showed that they were highly associated
(P < 1.10 9 107). The Amerindian ancestry CK/MM
is located close to IL28B on chromosome 19 (19q13),
but they were not in genotypic linkage disequilibrium
(rs8099917, P = 0.14; rs12979860, P = 0.80).
IL28B rs12979860
In rs12979860 SNP, C allele frequency was 0.457 with a
greater frequency in the SVR group (0.585 in the SVR
group vs NR/R 0.450, P = 1.7 9 103); it was also more
frequent among sustained virological responders when
we analysed HCV genotype 1 patients (0.623 in SVR vs
0.440 in NR/R group, P = 3.35 9 103) and genotype
2/3 (0.614 in SVR vs 0.450 in NR/R group, P = 0.15)
infected subjects separately. When all patients were anal-
ysed, T allele frequency was 0.547, and it was higher in
the NR/R groups (NR/R group T frequencies: in the
whole sample, 0.550; HCV genotype 1, 0.557 and HCV
genotype 2/3, 0.538).
We found similar genotype frequency distribution in
the HCV genotype 1 subgroup [C/C 23.5% (n = 39),
C/T 56% (n = 93) and T/T 20.5% (n = 34)] and among
patients with HCV genotypes 2/3 [C/C 27.3% (n = 15),
C/T 50.9% (n = 28) and T/T 21.8% (n = 12)]. The C/C
genotype was significantly associated with SVR and C/T
and T/T with failure to therapy when all HCV genotypes
were analysed together and when they were analysed sep-
arately (HCV genotype 1 and HCV genotypes 2/3). The
frequency of SVR among patients with C/C genotype in
the whole sample, HCV genotype 1 and HCV genotypes
2/3 groups was 67, 64 and 73% respectively (Fig. 1A).
We observed a strong association between C/C genotype
and SVR when compared with the other two genotypes
combined (C/T + T/T) (P = 4.64 9 106, OR 4.55).
Similar results were observed in the HCV genotype 1
(P = 5.32 9 105, OR 4.69) and HCV genotypes 2/3
(P = 3.66 9 102, OR 4.13) subgroups (Fig. 1B).
IL28B rs8099917
By analysing rs8099917, a higher frequency of T allele
(0.807) and lower of G allele (0.193) were observed in a
whole sample. We found similar genotype frequency
distribution in the HCV genotype 1 subgroup [T/T 62%
(n = 103), G/T 34.3% (n = 57) and G/G 3.6% (n = 6)]
and among patients with HCV genotypes 2/3 [T/T
64.3% (n = 36), G/T 33.9% (n = 19) and G/G 1.7%
(n = 1)]. The G/G and G/T genotypes were significantly
associated with failure to obtain SVR when all HCV
genotypes were analysed together and when they were
analysed separately (HCV genotype 1 and HCV geno-
types 2/3). On the other hand, the frequency of SVR was
greater among patients with T/T genotype compared
with the other two genotypes (Fig. 2A). The G allele was
associated with NR/R to antiviral therapy, and its fre-
quency was 0.130 in SVR group vs 0.240 in NR/R group,
P = 6.5 9 103. Similar results were found for HCV
genotype1 group (G 0.120 in the SVR group vs G 0.240
in the NR/R group, P = 3.00 9 102) and for HCV
genotypes 2/3 group (G 0.110 in the SVR group vs G
0.250 in the NR/R group, P = 0.05).
We observed a strong association between G/G + G/T
genotypes and failure to obtain SVR when compared
with the T/T genotype (P = 2.78 9 103, OR 1.38).
Similar results were observed in the HCV genotype 1
(P = 3.03 9 102, OR 1.32) and HCV genotypes 2/3
(P = 4.96 9 102, OR 1.57) subgroups (Fig. 2B).
Genomic ancestry and IL28B polymorphisms
By analysing genetic contribution according to IL28B
rs12979860 genotypes, we found that among HCV type
1 patients with the C/C genotype, genomic ancestry does
Table 2. Allele*1 frequencies from ancestry informative markers
in the ancestral populations and in the admixed study population
with chronic hepatitis C (CHC)
Markers
Ancestral populations*1
Study population
African European Amerindian CHC*2
Fynull 0.001 0.998 1.000 0.657
APO 0.415 0.903 0.645 0.692
LPL 0.971 0.492 0.442 0.634
AT3-I/D 0.858 0.280 0.061 0.531
SB19.3 0.420 0.925 0.977 0.575
CKMM 0.164 0.313 0.904 0.352
PV92 0.225 0.152 0.792 0.275
*1Frequencies by Shriver (38).
*2Frequencies from an admixed population with CHC.
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not appear to interfere with response to antiviral ther-
apy, as European, African and Amerindian genetic con-
tribution were similar between sustained virological
responders and non-responders/relapsers. On the other
hand, among HCV type 1 patients with the T/T and C/T
genotypes, genomic ancestry does appear to interfere
with response to antiviral therapy. African genetic contri-
bution was significantly greater among patients in the
NR/R group compared with the SVR group; on the other
hand, Amerindian ancestry genetic contribution was sig-
nificantly higher in the SVR group. European ancestry
was associated with SVR only among patients with the
T/T genotype (Table 3). There was no significant associa-
tion between therapy response and genetic ancestry con-
tribution amongHCV genotypes 2/3 infected patients.
Of note, ancestry classified using self-reported or
morphological phenotypic methods did not interfere
with HCV therapy response in any of the IL28B
rs12979860 genotypes (Table 4).
Analysis with rs8099917 showed that among HCV
genotype 1 patients with the T/T, genomic ancestry
appears to interfere with response to antiviral therapy.
African genetic contribution was significantly greater
among patients in the NR/R group compared with the
SVR group; Amerindian and European ancestry genetic
contribution were greater in the SVR group (Table 3).
There was no statistically significant association between
therapy response and genetic ancestry contribution
among HCV genotypes 2/3 infected patients.
Of note, in patients with the T/T genotype, there were
a greater frequency of African-descents classified using
morphological phenotypic and self-reported ancestry
methods among non-responders/relapsers (Table 4).
Discussion
This study showed that in an admixed population, both
rs12979860 and rs8099917 IL28B polymorphisms are
Fig. 1. IL28B rs12979860 according to therapy response. (A) Analysis considering IL28B genotypes separately. (B) Analysis considering C/T
and T/T genotypes together vs C/C.
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strong predictors of response to combination of antivi-
ral therapy with pegylated interferon alpha and ribavirin
in chronically infected patients with HCV. These results
are in agreement with data showed in previous studies
from more homogenous populations (10, 11). Of note,
IL28B polymorphisms were influenced by genetic ances-
try in subgroups of patients.
We evaluated a tri-hybrid population, not only mixed
with a predominantly African ancestry contribution but
also with a European and Amerindian contribution.
This has been confirmed by genetic AIMs of ancestry
and by the historical context of the Brazilian coloniza-
tion (33). The AIMs SB19.3, CKMM, AT3 and Fy-Null
were not in Hardy–Weinberg equilibrium, but in an
admixed population as ours, and it might reflect recent
admixture or wedding among phenotipically similar
people. In admixed populations, it should be necessary
to use more objective methods to evaluate the patients’
ethnic background when estimating patients’ health
outcomes. Therefore, we have chosen AIMs with high
frequency differential (higher than 48%) that have been
previously studied in the Brazilian population with good
accuracy to measure ancestry (27). As a result of the
high frequency of racial inter-mixing over time, we
observed a heterogeneous population, and probably this
is the reason that self-reported and phenotypic racial
features were poor predictors of genetic ancestry and
SVR in our study. On the other hand, even in Europe,
North America and Africa where there appears to be a
low frequency of racial inter-mixing, self-reported
ancestry and morphological ancestry methods can be
useful to define race and to predict SVR to antiviral
therapy for CHC patients.
Many GWAS have reported associations of different
SNPs in IL28B with response to antiviral therapy. Partic-
ularly in HCV genotype 1 infected patients, these SNPs
Fig. 2. IL28B rs8099917 according to therapy response. (A) Analysis considering IL28B genotypes separately. (B) Analysis considering G/G
and G/T genotypes together vs T/T.
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(rs12979860 C/C, rs8099917 T/T and rs12980275 A/A)
have been demonstrated to be highly associated with
SVR to pegylated interferon/ribavirin treatment. Those
results also showed an association between self-reported
ancestry and SVR. Of note, the rs12979860 is just 4378
bases from rs8099917, and it has been described as a
high linkage between them (10, 16). In our study, we
also found this high linkage as well.
In IL28B rs12979860, we detected a 24% C/C geno-
type frequency among our study sample. This is lower
than the frequency of 35% found in a previous study
when all ethnic groups were analysed. However, it
appears to be an intermediate prevalence compared with
the C/C genotype frequency of 16% among African
Americans and 39% among European Americans (10).
It is interesting to speculate that this intermediate fre-
quency reflects the ethnic admixture of our population.
Of note, the C allele frequency in our study sample was
closer to one observed among the African Americans in
the North American study. This reflects the higher rate
of heterozygotes detected in our sample, which perhaps
is related to the greater African genetic contribution in
our population. It is important to mention that in our
study, the C/C genotype in rs12979860 was a strong pre-
dictor of SVR for HCV genotype 1 (OR 4.69) and HCV
genotype 2/3 (OR 4.13). A previous US study also
showed C/C in rs12979860 to be a strong predictor of
SVR for HCV genotype 1 and HCV genotype 2/3 (34).
However, the C/C genotype is still controversial as a
predictor of SVR among HCV genotypes 2/3 infected
Table 3. Genetic ancestry contribution according to IL28B genotypes and antiviral therapy response
rs12979860 rs8099917
Ancestry
P
Ancestry
PMean SD Mean SD
HCV genotype 1
CC European SVR 0.339 0.021 0.50 GG European SVR 0.372 0.65
NR/R 0.356 0.093 NR/R 0.314 0.106
Amerindian SVR 0.322 0.023 0.37 Amerindian SVR 0.330 0.65
NR/R 0.300 0.084 NR/R 0.296 0.063
African SVR 0.338 0.037 0.86 African SVR 0.299 0.66
NR/R 0.343 0.113 NR/R 0.369 0.137
CT European SVR 0.330 0.024 0.50 GT European SVR 0.343 0.023 0.99
NR/R 0.320 0.103 NR/R 0.343 0.103
Amerindian SVR 0.322 0.031 2.28 9 103 Amerindian SVR 0.332 0.026 4.7 9 102
NR/R 0.280 0.088 NR/R 0.284 0.079
African SVR 0.331 0.086 6.61 9 102 African SVR 0.294 0.096 0.12
NR/R 0.377 0.125 NR/R 0.356 0.126
TT European SVR 0.349 0.026 2.16 9 102 TT European SVR 0.334 0.023 0.07
NR/R 0.309 0.067 NR/R 0.309 0.085
Amerindian SVR 0.326 0.025 3.77 9 103 Amerindian SVR 0.319 0.027 4.0 9 103
NR/R 0.274 0.067 NR/R 0.279 0.087
African SVR 0.325 0.020 1.51 9 103 African SVR 0.345 0.040 5.0 9 103
NR/R 0.413 0.114 NR/R 0.399 0.116
HCV genotypes 2/3
CC European SVR 0.324 0.025 0.79 GG European SVR –
NR/R 0.328 0.035 NR/R
Amerindian SVR 0.338 0.028 0.40 Amerindian SVR –
NR/R 0.370 0.111 NR/R
African SVR 0.339 0.039 0.47 African SVR –
NR/R 0.374 0.139 NR/R
CT European SVR 0.333 0.023 0.46 GT European SVR 0.333 0.013 0.73
NR/R 0.356 0.089 NR/R 0.348 0.070
Amerindian SVR 0.308 0.020 0.47 Amerindian SVR 0.314 0.020 0.78
NR/R 0.290 0.071 NR/R 0.301 0.079
African SVR 0.354 0.038 0.94 African SVR 0.352 0.028 0.99
NR/R 0.350 0.139 NR/R 0.351 0.132
TT European SVR 0.362 0.025 0.82 TT European SVR 0.332 0.028 0.23
NR/R 0.353 0.073 NR/R 0.355 0.090
Amerindian SVR 0.339 0.033 0.35 Amerindian SVR 0.331 0.030 0.25
NR/R 0.302 0.069 NR/R 0.308 0.081
African SVR 0.300 0.048 0.49 African SVR 0.335 0.045 0.55
NR/R 0.346 0.116 NR/R 0.355 0.133
In hepatitis C virus (HCV) genotype 2/3 NR/R subgroup nobody had G/G genotype and only one in sustained virological response (SVR).
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patients. In a recent published European study, C/C
genotype was a strong predictor of SVR; however, in
another study, it was a predictor of SVR only in patients
who had not achieved RVR (21). Also, we found a
slightly higher frequency (28%) of this protective geno-
type among HCV genotype 2/3 infected patients com-
pared with HCV genotype 1 in contrast to greater
frequencies described by other authors (35–37).
We evaluated the relationship between genetic ances-
try contribution, IL28B rs12979860 and response to
HCV therapy. Interestingly, HCV genotype 1 patients
who had the C/C genotype did not have their chances of
obtaining SVR influenced by genetic ancestry contribu-
tion. On the other hand, genetic ancestry contribution
interfered with the antiviral HCV genotype 1 response
rates of subjects who had the C/T and especially T/T
genotype. In these subgroups of patients, a higher Afri-
can genomic contribution was associated with fewer
chances to obtain SVR, and a greater Amerindian and
European (the latter for T/T genotype only) was associ-
ated with more chances to obtain SVR. Therefore, the
C/C genotype appears to be a more important marker
of therapy response than ancestry in our admixed popu-
lation. From another standpoint, patients who have the
other two unfavourable genotypes are influenced by
other factors such as the amount of genetic contribution
they have received. Of note, when we analysed our pop-
ulation using phenotypic and self-reported ancestry,
there was no association between these classification
methods and response to antiviral therapy. Therefore,
our study showed that in admixed populations, they
should not be used to determine the chances of obtain-
ing SVR. North American studies have found that in
patients of European ancestry, the C/C genotype was
associated with a two-fold greater rate of SVR than the
T/T genotype, three-fold greater rate in African Ameri-
cans and two-fold higher rate in Hispanic populations
(10). Results from recent spontaneous HCV clearance
data have shown that the strength of the protective C/C
effect was similar in individuals of African and Euro-
pean ancestry (15).
As previously mentioned, Amerindian genetic ances-
try was a strong protective factor associated with SVR in
this admixed sample. Although we did not observe
a high Amerindian ancestry contribution (0.217), it was
more associated to SVR than European ancestry.
Table 4. Ancestry analysis classified according to morphological phenotypic characteristics and self-reported classification, IL28B genotypes
and antiviral therapy response
SVR (%) NR/R (%) P CI 95%
rs12979860
Phenotypic classification
Whites CC 18 (75.0) 6 (25.0) 0.38 0.616–6.49
African-descents 18 (60.0) 12 (40.0)
Whites CT 16 (32) 34 (68) 0.68 0.57–2.80
African-descents 19 (27.1) 51 (72.9)
Whites TT 7 (43.8) 9 (56.3) 0.52 0.46–5.83
African-descents 9 (32.1) 19 (67.9)
Self-reported classification
Whites CC 16 (80.0) 4 (20.0) 0.14 0.77–10.18
African-descents 20 (58.8) 14 (41.2)
Whites CT 11 (29.7) 26 (70.3) 1.00 0.45–2.43
African-descents 24 (28.9) 59 (71.1)
Whites TT 5 (50) 5 (50) 0.46 0.50–8.76
African-descents 11 (32.4) 23 (67.6)
rs8099917
Phenotypic classification
Whites GG 2 (50) 2 (50) 0.43 0.19–1.33
African-descents 0 3 (100)
Whites GT 10 (25.6) 29 (74.4) 1.00 0.78–1.35
African-descents 10 (27.8) 26 (72.2)
Whites TT 29 (61.7) 18 (38.3) 0.03 0.44–0.97
African-descents 37 (41.1) 53 (58.9)
Self-reported classification
Whites GG 1 (50) 1 (50) 1.00 0.12–13.96
African-descents 1 (20) 4 (80)
Whites GT 7 (24.1) 22 (75.9) 0.79 0.28–2.34
African-descents 13 (28.3) 33 (71.7)
Whites TT 24 (66.7) 12 (33.3) 0.01 1.27–6.24
African-descents 42 (41.6) 59 (58.4)
CI 95%, confidence interval 95%; NR/R, non-response or relapse; OR, odds ratio; P, P-value; SVR, sustained virological response.
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One Amerindian AIM (CKMM) is close to IL28B
rs12979860; however, they are not linked. In addition,
CKMM is a good marker to differentiate African, Euro-
pean and Amerindian populations with high differen-
tial frequency (23).
In IL28B rs8099917, we detected a high T allele fre-
quency (0.807), and it was significantly associated with
SVR. The G allele frequency was low (0.193), and it
was more frequent among non-responders/relapsers.
This is agreement with previous studies which found
that G allele was associated with failure to antiviral treat-
ment and T allele with SVR. The most significant associ-
ations were found in Asiatic populations (11, 12). Also,
the T/T genotype frequency in our admixed population
was 63% (HCV genotype 1, 62% and HCV genotypes
2/3, 64%), only slightly higher than the 58% frequency
found in HCV genotype 1 Swiss population (16).
We also evaluated the relationship between genetic
ancestry contribution, IL28B rs8099917 and response to
HCV therapy. Interestingly, in contrast to IL28B
rs12979860, HCV genotype 1 patients who had the
favourable genotype (T/T) had their chances of obtain-
ing SVR influenced by genetic ancestry contribution. As
this genotype was highly frequent in our population,
probably other factors such as the amount of genetic
contribution they have received are also important to
obtain SVR. A higher African genetic contribution was
associated with non-response to therapy, and again a
higher Amerindian contribution was a predictor of
SVR. These findings reinforce the protective role of the
Amerindian genomic ancestry for HCV treatment.
In summary, IL28B rs12979860 and rs8099917 were
predictors of therapy response in our admixed popula-
tion, for both HCV genotypes 1 and HCV genotypes 2/3
patients. IL28B rs12979860 C/C genotype was the most
important factor associated with SVR. In patients with
the unfavourable IL28B rs12979860 genotypes, a higher
African genomic contribution was associated with fewer
chances to obtain SVR, and a greater Amerindian and
European was associated with more chances to obtain
SVR. When we analysed our population using pheno-
typic and self-reported ancestry, there was no associa-
tion between these classification methods and response
to antiviral therapy. Although IL28B rs8099917 was a
predictor of therapy response among our patients, it
was not as strong as IL28B rs12979860.
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